Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy

Clinical Nephrology

Volumn 75, Issue 5, 2011, Pages 451-457

  Winoto, J ^a   Song, H ^a   Hines, C ^a   Nagaraja, H ^a   Rovin, B H ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cytochrome P450 system; Immunosuppression; Pharmacogenetics; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; CYP2C19 PROTEIN, HUMAN; N DEMETHYLASE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AFRICAN AMERICAN; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; EUROPEAN AMERICAN; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 79958709523     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106886     Document Type: Article

References (26)

1. Austin HA, Klippel JH, Balow JE, le Riche WG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Eng J Med. 1986; 314: 614-619.
2. Gourley MF, Austin HA, 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996; 125: 549-557.
3. Donadio JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978; 23: 1151-1155.
4. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro C, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992; 340: 741-745.
5. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, Group TALMS. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103-1112.
6. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis.N Eng J Med. 2004; 350: 971-980.
7. McKinley A, Park E, Spetie DN, Hackshaw K, Hebert LA, Rovin BH. Oral cyclophosphamide for lupus glomerulonephritis: an under-utilized therapeutic option. Clin J Am Soc Nephrol. 2009; 4: 1754-1760.
8. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon JP, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel G. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Eng J Med. 2005; 353: 2219-2228.
9. van Schaik RHN. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updates. 2008; 11: 77-98.
10. Pinto N, Ludeman SM, Dolan ME. Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics. 2009; 10: 1897-1903.
11. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumdpas DT, Balow JE, Flockhart DA, Illei GG. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 2004; 50: 2202-2210.
12. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl M-L. Bioactivation of cyclophosphamide. The role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol. 2003; 59: 103-109.
13. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001; 11: 399-415.
14. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome. Pharmacogenomics J. 2005; 5: 365-373.
15. Xie H-G, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol. 2001; 41: 815-850.
16. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269: 15419-15422.
17. Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int. 2008; 74: 799-807.
18. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010; 102: 1003-1009.
19. Guan S, Huang M, Li X, Chen X, Chan E, Zhou S-F. Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharmaceutical Res. 2006; 23: 1983-1990.
20. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, MarzoliniC, AcostaEP. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS. 2004; 18: 2391-2400.
21. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1, and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenetics Genomics. 2008; 18: 515-523.
22. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati VD, Salmon J, Radhakrishnan J. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003; 18: 2039-3046.
23. Dooley MA, Hogan S, Jennette JC, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int. 1997; 51: 1188-1195.
24. Kortunay S, Bozkurt A, Bathum L, Basci NE, Calguneri M, Brosen K, Sayaalp SO. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Ann Rheum Dis. 1999; 58: 182-185.
25. von Schmiedebert S, Fritsche E, Ronnau AC, Specker C, Golka K, Richter-Hintz D, Schuppe HC, Lehmann P, Ruzicka T, Esser C, Abel J, Gleichmann E. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol. 1999; 455: 147-152.
26. Yen J-H, Chen C-J, Tsai C-W, Lin C-H, Ou T-T, Hu C-J, Liu H.: Cytochrome P450 and manganese superoxide dismutase gene polymorphisms in systemic lupus erythematosus. Immunol Lett. 2003; 90: 19-24.